Roze bril schreef op 11 januari 2021 11:13:
[...]
Je moet niet teveel verwachten van DeTijd, die hebben al eerder aangegeven zich niet bezig te houden met kleine small-caps zoals Acacia.
In het laatste persbericht dat Acacia de wereld instuurde op 15 december zeggen ze dit over ByFavo:
BYFAVO was approved by the US Food and Drug Administration (FDA) on 2 July 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. It received its Schedule IV designation from the US Drug Enforcement Administration (DEA) on 5 October 2020.
DEA scheduling requirements between July and October this year delayed the final approval and finalization of the BYFAVO label, leading Acacia Pharma to request Cosmo to prioritize the BYFAVO processing schedule during a time when its facility would typically be closed. The agreement to amend the timing for this payment was reached in consideration for Cosmo modifying its production schedule and expediting its packaging and labelling production for BYFAVO.
Acacia Pharma is preparing to launch BYFAVO in the US as soon as possible in the coming weeks.
"In the coming weeks" is dan wel een rekbaar begrip, maar ik verwacht toch deze maand nog een bericht over de lancering. Er komen nog 14 beursdagen aan in januari. ;)
Geduld dames en heren, geduld.